Patents by Inventor Maren Watkins
Maren Watkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050214903Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: May 6, 2004Publication date: September 29, 2005Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero Olivera, G. Cartier, Maren Watkins, David Hillyard, J. McIntosh, Richard Layer, Robert Jones
-
Publication number: 20050214213Abstract: The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 4, 2005Publication date: September 29, 2005Applicants: University of Utah, CognetixInventors: Baldomero Olivera, J. McIntosh, Maren Watkins, James Garrett, Lourdes Cruz, Michelle Grilley, Robert Schoenfeld, Craig Walker, Reshma Shetty, Robert Jones
-
Publication number: 20050203003Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: ApplicationFiled: February 8, 2002Publication date: September 15, 2005Applicants: University of Utah Research Foundation, Cognetix, Inc., The Salk Institute for Biological StudiesInventors: A. Craig, David Griffin, Baldomero Olivera, Maren Watkins, David Hillyard, Julita Imperial, Lourdes Cruz, John Wagstaff, Richard Layer, Robert Jones, R. McCabe
-
Publication number: 20050159586Abstract: The invention relates to linear ?-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvillsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: December 22, 2004Publication date: July 21, 2005Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero Olivera, J. McIntosh, James Garrett, Craig Walker, Maren Watkins, Robert Jones
-
Publication number: 20050137132Abstract: The present invention is directed to kappaM (?M) conopeptide RIIIK and its use for blocking the flow of potassium ions through voltage-gated potassium channels. The ?M conopeptides include unglycosylated and O-glycosylated peptides.Type: ApplicationFiled: July 16, 2004Publication date: June 23, 2005Applicants: University of Utah Research Foundation, Max Planck Institut for Experimental MedicineInventors: Baldomero Olivera, Maren Watkins, Heinrich Terlau, Michael Ferber
-
Publication number: 20050096270Abstract: The invention relates to relatively short peptides (termed 1-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: ApplicationFiled: July 20, 2004Publication date: May 5, 2005Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Craig Walker, Reshma Shetty, Elsie Jimenez, J. McIntosh, Baldomero Olivera, Maren Watkins, Robert Jones, Gregory Shen
-
Publication number: 20050032705Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: July 21, 2004Publication date: February 10, 2005Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Maren Watkins, Baldomero Olivera, David Hillyard, J. McIntosh, Robert Jones
-
Publication number: 20040204362Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The &agr;-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.Type: ApplicationFiled: May 6, 2004Publication date: October 14, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, Richard T. Layer, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Robert Schoenfeld, Jacob Scott Nielsen, Robert M. Jones
-
Publication number: 20040192886Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 21, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Patent number: 6797808Abstract: The invention relates to relatively short peptides (termed &agr;-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: January 28, 2000Date of Patent: September 28, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
-
Publication number: 20040176278Abstract: The present invention is directed to &bgr;-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the &bgr;-superfamily conotoxin peptides and encoding &bgr;-superfamily conotoxin propeptides, as well as the &bgr;-superfamily conotoxin propeptides.Type: ApplicationFiled: May 5, 2004Publication date: September 9, 2004Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Robert M. Jones, Baldomero M. Olivera, Maren Watkins, James E. Garrett
-
Patent number: 6767895Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: GrantFiled: June 29, 2001Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Craig S. Walker, Reshma Shetty, Elsie C. Jimenez, J. Michael McIntosh, Baldomero M. Olivera, Maren Watkins, Robert M. Jones, Gregory S. Shen
-
Patent number: 6762165Abstract: The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: December 28, 2000Date of Patent: July 13, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, G. Edward Cartier, Maren Watkins, David R. Hillyard, J. Michael McIntosh, Richard T. Layer, Robert M. Jones
-
Publication number: 20040132663Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: January 29, 2004Publication date: July 8, 2004Applicants: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier
-
Patent number: 6696408Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 24, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Publication number: 20030181368Abstract: The present invention is directed to kappaA (&kgr;A) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The &kgr;A conopeptides include unglycosylated and O-glycosylated peptides.Type: ApplicationFiled: May 7, 2002Publication date: September 25, 2003Inventors: Richard T. Layer, Karen E. Pemberton, Robert M. Jones, James L. Garrett, Baldomero M. Olivera, J. Michael McIntosh, David R. Hillyard, Michelle Grilley, Maren Watkins, Ameurfina D. Santos, Glenn Zafaralla, A. Grey Craig
-
Patent number: 6624288Abstract: This invention relates to relatively short peptides about 25-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include three cyclizing disulfide linkages and one or more &ggr;-carboxyglutamate residues.Type: GrantFiled: December 15, 1998Date of Patent: September 23, 2003Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Michael Fainzilber, Karel S. Kits, Alma L. Burlingame, Baldomero M. Olivera, Craig Walker, Maren Watkins, Reshma Shetty, Lourdes J. Cruz, Julita Imperial, Clark Colledge
-
Publication number: 20030170222Abstract: The present invention is directed to &bgr;-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the &bgr;-superfamily conotoxin peptides and encoding &bgr;-superfamily conotoxin propeptides, as well as the &bgr;-superfamily conotoxin propeptides.Type: ApplicationFiled: January 29, 2002Publication date: September 11, 2003Applicant: University of Utah Research FoundationInventors: Robert M. Jones, Baldomero M. Olivera, Maren Watkins, James E. Garrett
-
Publication number: 20030144210Abstract: The invention relates to &ggr;-carboxyglutamate containing conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 31, 2002Publication date: July 31, 2003Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Craig S. Walker, Maren Watkins, Robert M. Jones
-
Publication number: 20030119731Abstract: The invention relates to &ohgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents, as cardiovascular agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: June 26, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier